Rifampicin Capsules

Each pill of this product contains 0.15g of rifampicin, and the content is orange-red or dark red powder. Rifampicin is a semi-synthetic broad-spectrum bactericidal agent. This product is used in combination with other anti-tuberculosis drugs for the initial treatment and retreatment of tuberculosis. It is also suitable for asymptomatic meningococcal carriers to eliminate Nepi meningococci in the nasopharynx (this product is not suitable for the treatment of meningococcal infection). Rifampicin can also be considered for contact with influenza bacilli to prevent infection; combined with other drugs for the treatment of leprosy and atypical mycobacterium infection.

The main ingredient is rifampicin.

This product is a capsule containing bright red or dark red crystalline powder.

1. This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment of various tuberculosis diseases, including the treatment of tuberculous meningitis. 2. This product is used in combination with other drugs to treat leprosy and non-tuberculous mycobacterial infections. 3. This product can be used in combination with vancomycin (intravenous) for severe infections caused by methicillin-resistant Staphylococci. The combination of rifampicin and erythromycin is used for severe Legionella infections. 4. It is used for asymptomatic carriers of Neisseria meningitidis to eliminate Neisseria meningitidis in the nasopharynx; but it is not suitable for the treatment of Neisseria meningitidis infections.

1. For anti-tuberculosis treatment of adults: Oral, 0.45g-0.60g per day, taken on an empty stomach, not more than 1.2g per day; for children over 1 month old, 10-20mg/kg per day, taken on an empty stomach, not more than 0.6g per day. 2. For carriers of Neisseria meningitidis: 5mg/kg per day, once every 12 hours for 2 consecutive days; for children over 1 month old, 10mg/kg per day, once every 12 hours for 4 consecutive days. 3. For elderly patients, oral, 10mg/kg per day, taken on an empty stomach.

Chills, dizziness, fever, chills, loss of appetite, nausea and vomiting.

1. Patients who are allergic to this product are prohibited from using it. 2. Patients with severe liver dysfunction are prohibited from using it. 3. Patients with biliary obstruction are prohibited from using it. 4. Pregnant women are prohibited from using it.

Precautions for children: The safety of this product for children under 5 years old has not been established. Precautions for pregnancy and lactation: 1. Rifampicin can cross the placenta and has caused teratogenesis in animal experiments. Although there are no reports of teratogenesis in humans, there is currently insufficient information to indicate that it can be safely used during pregnancy. 2. Rifampicin can be excreted in breast milk. Lactating women should fully weigh the pros and cons before deciding whether to use the drug. Precautions for the elderly: Elderly patients have decreased liver function and the dosage should be reduced as appropriate.

1. Drinking alcohol daily while taking rifampicin can increase the incidence of rifampicin hepatotoxicity and increase the metabolism of rifampicin. The rifampicin dose needs to be adjusted and the patient should be closely monitored for signs of hepatotoxicity. 2. When adrenocortical hormones (glucocorticoids, mineralocorticoids), anticoagulants, coumarin or indanedione derivatives, oral hypoglycemic drugs, corticotropin, dapsone, digitalis glycosides, disopyramide, quinidine, etc. are used in combination with rifampicin, the latter can stimulate the activity of liver microsomal enzymes, which can reduce the efficacy of the above drugs. Therefore, except for digoxin and dapsone, the above drugs need to be adjusted in dose before and during rifampicin. When this product is used in combination with coumarins or indanediones, the prothrombin time should be measured daily or regularly to adjust the dose accordingly. 3. Para-aminosalicylate can affect the absorption of rifampicin, resulting in a decrease in the blood concentration of rifampicin; when patients take para-aminosalicylate and rifampicin, the two drugs should be separated by at least 6 hours. 4 Rifampicin can stimulate the metabolism of estrogen or reduce its enterohepatic circulation, reduce the effect of oral contraceptives, lead to irregular menstruation, intermenstrual bleeding and unplanned pregnancy. When patients take rifampicin, they should switch to other contraceptive methods. 5 Rifampicin can induce liver microsomal enzymes, increase the metabolism of anti-tumor drugs dacarbazine and cyclophosphamide, the formation of alkylated metabolites, and promote the decrease of white blood cells, so the dose needs to be adjusted. 6 The combination of isoniazid with rifampicin or miconazole (intravenous) and ketoconazole can increase the risk of hepatotoxicity, especially in patients with existing liver damage and isoniazid fast acetylation. In addition, the combination of isoniazid or rifampicin with miconazole or ketoconazole can reduce the blood concentration of the latter two, so this product and isoniazid should not be used in combination with imidazoles. 7 The combination of rifampicin and diazepam (diazepam) can increase the elimination of the latter and reduce its blood concentration, so the dose needs to be adjusted. 8 Rifampicin combined with ethionamide can aggravate its adverse reactions. 9 Rifampicin can increase the degradation of levothyroxine in the liver, so the dose of levothyroxine should be increased when the two are used together. Rifampicin can also increase the metabolism of methadone and mexiletine in the liver, causing methadone withdrawal symptoms and reduced mexiletine blood concentrations, so the latter two need to adjust the dose when used together. Rifampicin can increase the metabolism of phenytoin sodium in the liver, so the blood concentration of phenytoin sodium should be measured and the dosage adjusted when the two are used together. 10 Probenecid can compete with rifampicin for uptake by liver cells, increasing the blood concentration of rifampicin and producing toxic reactions. However, this effect is unstable, so it is usually not advisable to add bispropenecid to increase the blood concentration of rifampicin.

Sealed. Store in a dry and dark place. Valid for two years

0.15 g

24 months.

Guangdong Huanan Pharmaceutical Group Co., Ltd.

• Founded in:

  1986-08-11

• Address:

  Information Industry Park, Xihu Industrial Zone, Shilong Town, Dongguan City

• Tax NO.:

  91441900281802156P

• Registered Funds:

  55 million yuan

• Email:

  Log in to view